Find a Physician | How to Contribute | Contact Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial NU MSK12S01

Title
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination with Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
Principal Investigator
Mark Agulnik
Details
  • Status: Accepting New Patients
  • Study Type: Therapeutic, Treatment
  • Protocol No:.NU MSK12S01
Purpose
The purpose of this study is to find out what effects (good and/or bad)the combination of gemcitabine, docetaxel and pazopanib has on soft tissue sarcoma (STS).
Overview
The standard treatment for extremity sarcoma (in the soft tissue) is surgical resection (removal of the tumor). This is usually followed by radiation therapy. Sometimes the cancer comes back (recurrence). Recently, it has been suggested that chemotherapy may help to reduce the recurrence of sarcoma. Gemcitabine and docetaxel is a commonly used drug combination used for the treatment of advanced soft tissue sarcomas. Pazopanib can be effective treating advanced sarcoma in cases where prior chemotherapy was received. Combining these 3 drugs together is experimental.
Eligibility
Some of the eligibility criteria include:
  • Participants must be 18 years of age or older.
  • Participants must sarcoma in an extremity (arms or legs).
  • Participants must have cancer that may be removed with surgery.
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
All participants will receive the same dose of gemcitabine and docetaxel. Depending on when they enroll they will receive one of three possible doses of pazopanib. Participants will receive 2 cycles (each cycle is 21 days). After 2 cycles of treatment participants will be assessed. If the treatment is helping then they will receive 2 more cycles. If the cancer appears to be growing, then no further treatment will be given. In either case, surgery will follow treatment with participants receiving radiation therapy after that.
Contact
Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
312.695.1102
cancertrials@northwestern.edu

Find Related Clinical Trials

Browse by Disease Sites

Other Clinical Trials by Mark Agulnik

last updated: 19-Sep-14 02:46 AM

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.